Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction

Renato Maserati, Micaela Brandolini, Annamaria Cattelan, Anna Orani, Laura Sighinolfi, Massimo Andreoni, Alessia Uglietti, Giovanni Guaraldi, Giovanni Sotgiu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To assess the efficacy and the tolerability of once-daily (QD) versus twice-daily (BID) nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in virologically suppressed, HIV-positive patients switched from protease inhibitor (PI)-based HAART.Eligible patients were enrolled in the multicenter trial if HIV RNA levels were

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalCurrent HIV Research
Volume9
Issue number3
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Nevirapine
Highly Active Antiretroviral Therapy
Protease Inhibitors
HIV
Multicenter Studies
RNA

Keywords

  • Adverse events
  • Antiretroviral therapy
  • HIV
  • Nevirapine
  • Once-daily
  • Therapy switch

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction. / Maserati, Renato; Brandolini, Micaela; Cattelan, Annamaria; Orani, Anna; Sighinolfi, Laura; Andreoni, Massimo; Uglietti, Alessia; Guaraldi, Giovanni; Sotgiu, Giovanni.

In: Current HIV Research, Vol. 9, No. 3, 04.2011, p. 166-173.

Research output: Contribution to journalArticle

Maserati, R, Brandolini, M, Cattelan, A, Orani, A, Sighinolfi, L, Andreoni, M, Uglietti, A, Guaraldi, G & Sotgiu, G 2011, 'Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction', Current HIV Research, vol. 9, no. 3, pp. 166-173. https://doi.org/10.2174/157016211795945232
Maserati, Renato ; Brandolini, Micaela ; Cattelan, Annamaria ; Orani, Anna ; Sighinolfi, Laura ; Andreoni, Massimo ; Uglietti, Alessia ; Guaraldi, Giovanni ; Sotgiu, Giovanni. / Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction. In: Current HIV Research. 2011 ; Vol. 9, No. 3. pp. 166-173.
@article{48dac5faa7524d7caf5c835de1f745db,
title = "Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction",
abstract = "To assess the efficacy and the tolerability of once-daily (QD) versus twice-daily (BID) nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in virologically suppressed, HIV-positive patients switched from protease inhibitor (PI)-based HAART.Eligible patients were enrolled in the multicenter trial if HIV RNA levels were",
keywords = "Adverse events, Antiretroviral therapy, HIV, Nevirapine, Once-daily, Therapy switch",
author = "Renato Maserati and Micaela Brandolini and Annamaria Cattelan and Anna Orani and Laura Sighinolfi and Massimo Andreoni and Alessia Uglietti and Giovanni Guaraldi and Giovanni Sotgiu",
year = "2011",
month = "4",
doi = "10.2174/157016211795945232",
language = "English",
volume = "9",
pages = "166--173",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction

AU - Maserati, Renato

AU - Brandolini, Micaela

AU - Cattelan, Annamaria

AU - Orani, Anna

AU - Sighinolfi, Laura

AU - Andreoni, Massimo

AU - Uglietti, Alessia

AU - Guaraldi, Giovanni

AU - Sotgiu, Giovanni

PY - 2011/4

Y1 - 2011/4

N2 - To assess the efficacy and the tolerability of once-daily (QD) versus twice-daily (BID) nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in virologically suppressed, HIV-positive patients switched from protease inhibitor (PI)-based HAART.Eligible patients were enrolled in the multicenter trial if HIV RNA levels were

AB - To assess the efficacy and the tolerability of once-daily (QD) versus twice-daily (BID) nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in virologically suppressed, HIV-positive patients switched from protease inhibitor (PI)-based HAART.Eligible patients were enrolled in the multicenter trial if HIV RNA levels were

KW - Adverse events

KW - Antiretroviral therapy

KW - HIV

KW - Nevirapine

KW - Once-daily

KW - Therapy switch

UR - http://www.scopus.com/inward/record.url?scp=79959321686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959321686&partnerID=8YFLogxK

U2 - 10.2174/157016211795945232

DO - 10.2174/157016211795945232

M3 - Article

C2 - 21443516

AN - SCOPUS:79959321686

VL - 9

SP - 166

EP - 173

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 3

ER -